A 19-year-old male, on treatment for MDR-TB, presented with complaints of localized swelling over face, reddish discoloration of limbs, and hypopigmented patches over body since 1 month. He was on Category IV directly observed treatment, short-course chemotherapy for the last 5½ months on the basis of sputum line probe assay report from Revised National Tuberculosis Control Program (RNTCP) accredited laboratory, which showed M. tuberculosis isolates, resistant to drugs isoniazid and rifampicin. The patient was taking kanamycin, ethionamide, pyrazinamide, ethambutol, levofloxacin, and cycloserine regularly. There was a history of leprosy 6 years back, for which the patient was treated for 6 months. The patient had a history of TB 5 years back which was treated with 9 months of daily regimen antitubercular therapy. Clinical examination revealed hypopigmented, dry, scaly plaque over upper arms [], hypoanesthetic plaque over right palm [], and erythematous plaque over right side cheek and nose []. Respiratory system examination revealed bilateral infraclavicular crepts.\nRoutine investigations were normal. Chest radiograph was suggestive of fibrotic lesions, bilateral upper lobes []. Sputum culture from RNTCP accredited laboratory at 4th month was positive for growth of M. tuberculosis.\nDermatology review was taken for skin lesions. The patient was diagnosed as multibacillary (MB) leprosy and started on multidrug therapy regimen (MB-MDT) consisting of rifampicin 600 mg once monthly, dapsone 100 mg daily, and clofazimine 300 mg once monthly and 50 mg daily. Biopsy of skin lesions was suggestive of mid-borderline leprosy. Two weeks later, the patient presented with increased erythema and pain over the skin lesions and appearance of new lesions []. The patient was diagnosed with Type I lepra reaction and started on analgesics and steroids (prednisolone). Prednisolone was given in the dose of 30 mg/day orally for the first 2 weeks and then gradually tapered over the next 4 weeks. It was thus stopped after a total duration of 6 weeks. MB-MDT was continued as per the National Leprosy Eradication Programme guidelines.\nThus, final diagnosis of MDR-TB with mid-borderline leprosy and Type I lepra reaction was made. Skin lesions markedly improved with treatment []. Patient's subsequent sputum cultures were negative and MDR-TB was thereafter managed as per the RNTCP guidelines.
A 49-year-old man, nonsmoker, was admitted to dermatology department and followed up for diffuse lepromatous leprosy. He was vaccinated with BCG and he had no past history of tuberculosis. Diagnosis of leprosy was documented based on histological and bacteriologic evidence: a slit skin smear from the ear lobe was positive for lepra bacilli (BI3+), histopathology from the lesion on the face showed granulomas consisting of epithelioid histiocytes and lymphocytes with central caseous surrounding vessels and nerves, and PCR of biopsy specimens were positive for Mycobacterium leprae. After successful treatment using dapsone (100 mg/day), rifampicin (600 mg/month), and clofazimine (300 mg/month and 50 mg/day) during twelve months, hypopigmented skin lesions on the trunk and congestive rhinitis disappeared and the slit skin smear was negative. One month after the end of the treatment, he presented with diffuse papulonodular lesions on the face and trunk, fever, and alteration of general status. On the basis of his symptoms, diagnosis of leprosy reaction (type II) was made and the patient was treated using prednisone at a dose of 40 mg/kg/day. Outcome was unfavorable after two months of corticotherapy, and we had to wait for two supplementary months before we could get clofazimine to add corticoid. After 1 month of this treatment, he presented with fever, weight loss, and asthenia. Clinical examination revealed fever of 39°C, nodular lesions over face, trunk, forearms, and dorsum of hands (Figures , , and ). He presented no neurologic impairment. Biological examination showed inflammatory syndrome: CRP 393 mg/L, total leukocyte count 16,2 × 109/L, neutrophilia 15,3 × 109/L, and lymphopenia 0,48 × 109/L. Serum creatinine and alanine aminotransferase were normal. HIV status was negative. Two out of three sputum samples were positive for acid fast bacilli. Chest tomography showed alveolar-interstitial opacities at the left lower lobe (). Bronchoscopy detected thickening of lower lobar bronchi, without malignancy in histopathology of biopsy specimens. The patient was treated by antitubercular treatment. One month after the onset of this treatment, there were only two nodular lesions on the trunk, fever disappeared, and general status improved.